Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Nov 10, 11:15 AMAchieve Life Sciences Inc reports fiscal quarterly results with non-GAAP EPS $-0.11 (+61% YoY) and revenue $0, beats EPS and revenue estimates
Index
RUT
Market Cap
653.94M
Enterprise Value
466.47M
Income
-111.71M
Sales
0.00M
Book/sh
1.65
Cash/sh
1.96
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
28
IPO
Oct 12, 1995
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.86
P/C
3.25
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
10.49
Current Ratio
10.49
Debt/Eq
0.08
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-1.38
EPS next Y
-0.73
EPS next Q
-0.20
EPS this Y
-9.78%
EPS next Y
46.62%
EPS next 5Y
-
EPS past 3/5Y
32.06% 25.38%
Sales past 3/5Y
- -
EPS Y/Y TTM
-0.17%
Sales Y/Y TTM
-
EPS Q/Q
59.45%
Sales Q/Q
-
Insider Own
32.16%
Insider Trans
-0.06%
Inst Own
57.17%
Inst Trans
49.05%
ROA
-86.44%
ROE
-104.23%
ROIC
-59.73%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-4.25%
SMA50
-11.41%
SMA200
11.48%
Trades
Shs Outstand
109.78M
Shs Float
69.81M
52W High
8.64 -26.45%
52W Low
2.62 142.56%
Volatility
8.23% 6.47%
ATR (14)
0.43
RSI (14)
41.81
Beta
2.41
Rel Volume
0.38
Avg Volume
1.47M
Volume
398,775
Perf Week
-0.31%
Perf Month
-9.21%
Perf Quarter
-16.27%
Perf Half Y
9.76%
Perf YTD
27.87%
Perf Year
34.64%
Perf 3Y
54.62%
Perf 5Y
-22.69%
Perf 10Y
-99.28%
Prev Close
6.45
Price
6.36
Change %
-1.47%
Consensus
Strong Buy
Avg. Price Target
$13.75
Implied Upside
+116.4%
Analysts9incl. previous ratings
Rating Distribution9 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 30, 2026Initiated
SF logoSStifel
Buy$18+183.2%
Aug 13, 2026Initiated
MS logoMMorgan Stanley
Overweight$13+104.6%
Jun 26, 2026Resumed
RJF logoRRaymond James
Strong Buy$20+214.7%
Apr 21, 2026Initiated
CCanaccord Genuity
Buy$13+104.6%
Nov 25, 2025Initiated
CCitizens JMP
Mkt Outperform$19+199.0%
Aug 21, 2025Initiated
HH.C. Wainwright
Buy$12+88.8%
Nov 14, 2024Initiated
RRodman & Renshaw
Buy$12+88.8%
Sep 27, 2024Initiated
RJF logoRRaymond James
Strong Buy$20+214.7%
May 10, 2023Reiterated
MMaxim Group
Buy$8 → $20+214.7%
Jun 23, 2021Initiated
OPY logoOOppenheimer
Outperform$23+261.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Richard AlistairDirectorAug 19 '26Sale8.4920,626175,177208,249Aug 21 04:30 PM
Stewart Richard AlistairDirectorAug 19 '26Proposed Sale7.5220,626155,108Aug 19 09:16 AM
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
Chief Legal OfficerMr. Erik Atkisson
CEODr. Andrew D. Goldberg M.D.
Chief Financial OfficerMr. Benjamin Halladay M.B.A.
VP of Finance & Principal Accounting OfficerMr. Jerry Wan
Senior Vice President of Marketing & CommunicationsMs. Kaitlyn Tuson